Antigenic drift

Last updated

Antigenic drift is a kind of genetic variation in viruses, arising from the accumulation of mutations in the virus genes that code for virus-surface proteins that host antibodies recognize. This results in a new strain of virus particles that is not effectively inhibited by the antibodies that prevented infection by previous strains. This makes it easier for the changed virus to spread throughout a partially immune population. Antigenic drift occurs in both influenza A and influenza B viruses.

Contents

(Confusion can arise with two very similar terms, antigenic shift and genetic drift. Antigenic shift is a closely related process; it refers to the more dramatic changes in the virus's surface proteins when the genetic material from two or more viruses mix together. Genetic drift is very different and much more broadly applicable; it refers to the gradual accumulation in any DNA sequence of random mutational changes that do not interfere with the DNA's function and thus that are not seen by natural selection.)

The immune system recognizes viruses when antigens on the surfaces of virus particles bind to immune receptors that are specific for these antigens. These receptors can be antibodies in the bloodstream or similar proteins on the surfaces of immune-system cells. This recognition is quite precise, like a key recognizing a lock. After an infection or after vaccination, the body produces many more of these virus-specific immune receptors, which prevent re-infection by this particular strain of the virus; this is called acquired immunity. However, viral genomes are constantly mutating, producing new forms of these antigens. If one of these new forms of an antigen is sufficiently different from the old antigen, it will no longer bind to the antibodies or immune-cell receptors, allowing the mutant virus to infect people who were immune to the original strain of the virus because of prior infection or vaccination.

In 1940s, Maurice Hilleman discovered antigenic drift, which is the most common way that influenza viruses change. [1] [2] [3] [4] A second type of change is antigenic shift, also discovered by Hilleman, [1] [2] where the virus acquires a completely new version of one of its surface-protein genes from a distantly related influenza virus. The rate of antigenic drift is dependent on two characteristics: the duration of the epidemic, and the strength of host immunity. A longer epidemic allows for selection pressure to continue over an extended period of time and stronger host immune responses increase selection pressure for development of novel antigens. [5]

In influenza viruses

In the influenza virus, the two relevant antigens are the surface proteins, hemagglutinin and neuraminidase. [6] The hemagglutinin is responsible for binding and entry into host epithelial cells while the neuraminidase is involved in the process of new virions budding out of host cells. [7] Sites recognized on the hemagglutinin and neuraminidase proteins by host immune systems are under constant selective pressure. Antigenic drift allows for evasion of these host immune systems by small mutations in the hemagglutinin and neuraminidase genes that make the protein unrecognizable to pre-existing host immunity. [8] Antigenic drift is this continuous process of genetic and antigenic change among flu strains. [9]

In human populations, immune (vaccinated) individuals exert selective pressure for single point mutations in the hemagglutinin gene that increase receptor binding avidity, while naive individuals exert selective pressure for single point mutations that decrease receptor binding avidity. [8] These dynamic selection pressures facilitate the observed rapid evolution in the hemagglutinin gene. Specifically, 18 specific codons in the HA1 domain of the hemagglutinin gene have been identified as undergoing positive selection to change their encoded amino acid. [10] To meet the challenge of antigenic drift, vaccines that confer broad protection against heterovariant strains are needed against seasonal, epidemic and pandemic influenza. [11]

As in all RNA viruses, mutations in influenza occur frequently because the virus' RNA polymerase has no proofreading mechanism, resulting in an error rate between 1×10−3 and 8×10−3 substitutions per site per year during viral genome replication. [9] Mutations in the surface proteins allow the virus to elude some host immunity, and the numbers and locations of these mutations that confer the greatest amount of immune escape has been an important topic of study for over a decade. [12] [13] [14]

Antigenic drift has been responsible for heavier-than-normal flu seasons in the past, like the outbreak of influenza H3N2 variant A/Fujian/411/2002 in the 2003–2004 flu season. All influenza viruses experience some form of antigenic drift, but it is most pronounced in the influenza A virus.[ citation needed ]

Antigenic drift should not be confused with antigenic shift, which refers to reassortment of the virus' gene segments. As well, it is different from random genetic drift, which is an important mechanism in population genetics.[ citation needed ]

See also

Notes

  1. 1 2 Oransky, Ivan (2005-05-14). "Maurice R Hilleman". The Lancet. 365 (9472): 1682. doi:10.1016/S0140-6736(05)66536-1. ISSN   0140-6736. PMID   15912596. S2CID   46630955.
  2. 1 2 Kurth, Reinhard (April 2005). "Maurice R. Hilleman (1919–2005)". Nature. 434 (7037): 1083. doi: 10.1038/4341083a . ISSN   1476-4687. PMID   15858560.
  3. D. J. D. Earn; J. Dushoff; S. A. Levin (2002). "Ecology and Evolution of the Flu". Trends in Ecology and Evolution. 17 (7): 334–340. doi:10.1016/S0169-5347(02)02502-8.
  4. A. W. Hampson (2002). "Influenza virus antigens and antigenic drift". In C. W. Potter (ed.). Influenza. Elsevier Science B. V. pp. 49–86. ISBN   978-0-444-82461-5.
  5. Boni, T; S. Cobey; P. Beerli; M. Pascual (2006). "Epidemic dynamics and antigenic evolution in a single season of influenza A". Proceedings of the Royal Society B . 273 (1592): 1307–1316. doi:10.1098/rspb.2006.3466. PMC   1560306 . PMID   16777717.
  6. Bouvier NM, Palese P (Sep 2008). "The biology of influenza viruses". Vaccine. 26 (Suppl 4): D49–53. doi:10.1016/j.vaccine.2008.07.039. PMC   3074182 . PMID   19230160.
  7. Nelson, M. I.; Holmes, E. C. (March 2007). "The evolution of pandemic influenza". Nature Reviews Genetics. 8 (3): 196–205. doi: 10.1038/nrg2053 . PMID   17262054. S2CID   221107.
  8. 1 2 Hensley, S. E.; Das, S. R.; Bailey, A. L.; Schmidt, L. M.; Hickman, H. D.; Jayaraman, A.; Viswanathan, K.; Raman, R.; Sasisekharan, R.; Bennink, J. R.; Yewdell, J. W. (30 October 2009). "Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift". Science. 326 (5953): 734–736. Bibcode:2009Sci...326..734H. doi:10.1126/science.1178258. PMC   2784927 . PMID   19900932.
  9. 1 2 Taubenberger, Jeffery K.; Kash, John C. (17 June 2010). "Influenza virus evolution, host adaptation and pandemic formation". Cell Host & Microbe. 7 (6): 440–451. doi:10.1016/j.chom.2010.05.009. PMC   2892379 . PMID   20542248.
  10. Bush, R. M.; K. Subbarao; N. J. Cox; W. M. Fitch (3 December 1999). "Predicting the evolution of human influenza A". Science. 286 (5446): 1921–1925. doi:10.1126/science.286.5446.1921. PMID   10583948. S2CID   2836600.
  11. Carrat F, Flahault A (September 2007). "Influenza vaccine: the challenge of antigenic drift". Vaccine. 25 (39–40): 6852–62. doi:10.1016/j.vaccine.2007.07.027. PMID   17719149.
  12. R. M. Bush; W. M. Fitch; C. A. Bender; N. J. Cox (1999). "Positive selection on the H3 hemagglutinin gene of human influenza virus". Molecular Biology and Evolution. 16 (11): 1457–1465. doi: 10.1093/oxfordjournals.molbev.a026057 . PMID   10555276.
  13. W. M. Fitch; R. M. Bush; C. A. Bender; N. J. Cox (1997). "Long term trends in the evolution of H(3) HA1 human influenza type A". Proceedings of the National Academy of Sciences of the United States of America. 94 (15): 7712–7718. Bibcode:1997PNAS...94.7712F. doi: 10.1073/pnas.94.15.7712 . PMC   33681 . PMID   9223253.
  14. D. J. Smith; A. S. Lapedes; J. C. de Jong; T. M. Bestebroer; G. F. Rimmelzwaan; A. D. M. E. Osterhaus; R. A. M. Fouchier (2004). "Mapping the antigenic and genetic evolution of influenza virus" (PDF). Science. 305 (5682): 371–376. Bibcode:2004Sci...305..371S. doi:10.1126/science.1097211. PMID   15218094. S2CID   1258353. Archived from the original (PDF) on 2019-03-07.

Further reading

Related Research Articles

<span class="mw-page-title-main">Antiviral drug</span> Medication used to treat a viral infection

Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Antiviral drugs are one class of antimicrobials, a larger group which also includes antibiotic, antifungal and antiparasitic drugs, or antiviral drugs based on monoclonal antibodies. Most antivirals are considered relatively harmless to the host, and therefore can be used to treat infections. They should be distinguished from virucides, which are not medication but deactivate or destroy virus particles, either inside or outside the body. Natural virucides are produced by some plants such as eucalyptus and Australian tea trees.

<i>Paramyxoviridae</i> Family of viruses

Paramyxoviridae is a family of negative-strand RNA viruses in the order Mononegavirales. Vertebrates serve as natural hosts. Diseases associated with this family include measles, mumps, and respiratory tract infections. The family has four subfamilies, 17 genera, and 78 species, three genera of which are unassigned to a subfamily.

<i>Influenza A virus</i> Species of virus

Influenza A virus (IAV) is a pathogen that causes the flu in birds and some mammals, including humans. It is an RNA virus whose subtypes have been isolated from wild birds. Occasionally, it is transmitted from wild to domestic birds, and this may cause severe disease, outbreaks, or human influenza pandemics.

<span class="mw-page-title-main">Antigenic shift</span> Process by which two or more different strains of a virus combine to form a new subtype

Antigenic shift is the process by which two or more different strains of a virus, or strains of two or more different viruses, combine to form a new subtype having a mixture of the surface antigens of the two or more original strains. The term is often applied specifically to influenza, as that is the best-known example, but the process is also known to occur with other viruses, such as visna virus in sheep. Antigenic shift is a specific case of reassortment or viral shift that confers a phenotypic change.

<span class="mw-page-title-main">Hemagglutinin (influenza)</span> Hemagglutinin of influenza virus

Influenza hemagglutinin (HA) or haemagglutinin[p] is a homotrimeric glycoprotein found on the surface of influenza viruses and is integral to its infectivity.

<i>Orthomyxoviridae</i> Family of RNA viruses including the influenza viruses

Orthomyxoviridae is a family of negative-sense RNA viruses. It includes seven genera: Alphainfluenzavirus, Betainfluenzavirus, Gammainfluenzavirus, Deltainfluenzavirus, Isavirus, Thogotovirus, and Quaranjavirus. The first four genera contain viruses that cause influenza in birds and mammals, including humans. Isaviruses infect salmon; the thogotoviruses are arboviruses, infecting vertebrates and invertebrates. The Quaranjaviruses are also arboviruses, infecting vertebrates (birds) and invertebrates (arthropods).

<span class="mw-page-title-main">Influenza A virus subtype H2N2</span> Subtype of Influenza A virus

Influenza A virus subtype H2N2 (A/H2N2) is a subtype of Influenza A virus. H2N2 has mutated into various strains including the "Asian flu" strain, H3N2, and various strains found in birds. It is also suspected of causing a human pandemic in 1889. The geographic spreading of the 1889 Russian flu has been studied and published.

<i>Influenza B virus</i> Species of virus

Influenza B virus is the only species in the genus Betainfluenzavirus in the virus family Orthomyxoviridae.

<i>Influenza C virus</i> Genus of viruses in the family Orthomyxoviridae

Influenza C virus is the only species in the genus Gammainfluenzavirus, in the virus family Orthomyxoviridae, which like other influenza viruses, causes influenza.

<span class="mw-page-title-main">H5N1 genetic structure</span>

H5N1 genetic structure is the molecular structure of the H5N1 virus's RNA.

<span class="mw-page-title-main">Virosome</span> Drug or vaccine delivery mechanism

A virosome is a drug or vaccine delivery mechanism consisting of unilamellar phospholipid membrane vesicle incorporating virus derived proteins to allow the virosomes to fuse with target cells. Viruses are infectious agents that can replicate in their host organism, however virosomes do not replicate. The properties that virosomes share with viruses are based on their structure; virosomes are essentially safely modified viral envelopes that contain the phospholipid membrane and surface glycoproteins. As a drug or vaccine delivery mechanism they are biologically compatible with many host organisms and are also biodegradable. The use of reconstituted virally derived proteins in the formation of the virosome allows for the utilization of what would otherwise be the immunogenic properties of a live-attenuated virus, but is instead a safely killed virus. A safely killed virus can serve as a promising vector because it won't cause infection and the viral structure allows the virosome to recognize specific components of its target cells.

Antigenic variation or antigenic alteration refers to the mechanism by which an infectious agent such as a protozoan, bacterium or virus alters the proteins or carbohydrates on its surface and thus avoids a host immune response, making it one of the mechanisms of antigenic escape. It is related to phase variation. Antigenic variation not only enables the pathogen to avoid the immune response in its current host, but also allows re-infection of previously infected hosts. Immunity to re-infection is based on recognition of the antigens carried by the pathogen, which are "remembered" by the acquired immune response. If the pathogen's dominant antigen can be altered, the pathogen can then evade the host's acquired immune system. Antigenic variation can occur by altering a variety of surface molecules including proteins and carbohydrates. Antigenic variation can result from gene conversion, site-specific DNA inversions, hypermutation, or recombination of sequence cassettes. The result is that even a clonal population of pathogens expresses a heterogeneous phenotype. Many of the proteins known to show antigenic or phase variation are related to virulence.

<span class="mw-page-title-main">Spike protein</span> Glycoprotein spike on a viral capsid or viral envelope

In virology, a spike protein or peplomer protein is a protein that forms a large structure known as a spike or peplomer projecting from the surface of an enveloped virus. The proteins are usually glycoproteins that form dimers or trimers.

<span class="mw-page-title-main">Influenza</span> Infectious disease, often just "the flu"

Influenza, commonly known as "the flu", is an infectious disease caused by influenza viruses. Symptoms range from mild to severe and often include fever, runny nose, sore throat, muscle pain, headache, coughing, and fatigue. These symptoms begin from one to four days after exposure to the virus and last for about 2–8 days. Diarrhea and vomiting can occur, particularly in children. Influenza may progress to pneumonia, which can be caused by the virus or by a subsequent bacterial infection. Other complications of infection include acute respiratory distress syndrome, meningitis, encephalitis, and worsening of pre-existing health problems such as asthma and cardiovascular disease.

<span class="mw-page-title-main">Viral neuraminidase</span>

Viral neuraminidase is a type of neuraminidase found on the surface of influenza viruses that enables the virus to be released from the host cell. Neuraminidases are enzymes that cleave sialic acid groups from glycoproteins. Neuraminidase inhibitors are antiviral agents that inhibit influenza viral neuraminidase activity and are of major importance in the control of influenza.

<span class="mw-page-title-main">Hemagglutinin</span>

In molecular biology, hemagglutinins are receptor-binding membrane fusion glycoproteins produced by viruses in the Paramyxoviridae family. Hemagglutinins are responsible for binding to receptors on red blood cells to initiate viral attachment and infection. The agglutination of red cells occurs when antibodies on one cell bind to those on others, causing amorphous aggregates of clumped cells.

<span class="mw-page-title-main">Reverse genetics</span> Method in molecular genetics

Reverse genetics is a method in molecular genetics that is used to help understand the function(s) of a gene by analysing the phenotypic effects caused by genetically engineering specific nucleic acid sequences within the gene. The process proceeds in the opposite direction to forward genetic screens of classical genetics. While forward genetics seeks to find the genetic basis of a phenotype or trait, reverse genetics seeks to find what phenotypes are controlled by particular genetic sequences.

Viral phylodynamics is defined as the study of how epidemiological, immunological, and evolutionary processes act and potentially interact to shape viral phylogenies. Since the coining of the term in 2004, research on viral phylodynamics has focused on transmission dynamics in an effort to shed light on how these dynamics impact viral genetic variation. Transmission dynamics can be considered at the level of cells within an infected host, individual hosts within a population, or entire populations of hosts.

<span class="mw-page-title-main">Universal flu vaccine</span> Vaccine that prevents infection from all strains of the flu

A universal flu vaccine is a flu vaccine that is effective against all influenza strains regardless of the virus sub type, antigenic drift or antigenic shift. Hence it should not require modification from year to year. As of 2021 no universal flu vaccine had been approved for general use, several were in development, and one was in clinical trial.

<i>Influenza D virus</i> Species of virus

Influenza D virus is a species in the virus genus Deltainfluenzavirus, in the family Orthomyxoviridae, that causes influenza.